AzTrials
AzTrials

Neonatal Respiratory Distress SyndromePhase 2MINI T-RexNCT06975189

MINImising Total Radiation EXposure in Preterm Infants

A Phase 2 study testing Lung ultrasound group in people with Neonatal Respiratory Distress Syndrome and PreTerm Neonate, run by Western Health, Australia at 1 site in Australia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Being born too early (preterm birth) is the leading cause of death in children world-wide. In Australia, 97% of very preterm babies who are admitted to Neonatal Intensive Care Units need breathing support after birth to survive. Read more about this study

Who is it for?
Ages Up to 24 hours
What is being tested?
Lung ultrasound group
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
180 participants
Where
1 siteAustralia
Study dates
13 Apr 2026to 1 Dec 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 24 hours
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • All infants born <32 weeks' gestation and admitted to the neonatal intensive care unit (NICU) who require lung imaging for respiratory indications will be considered eligible. Each infant must meet all the following criteria to be enrolled in this study:
  • The infant is born from 22 to 31+6 weeks' gestation by best obstetric estimate and admitted to the NICU
  • The infant is considered to require lung imaging for respiratory indications
  • The infant has a parent/guardian who can provide informed consent.

Who cannot join

  • The infant will only require CXR to be performed solely to confirm device position i.e. central line, endotracheal tube, gastric tubes
  • The infant will only require CXR to be performed for specifically for non-respiratory indications i.e. assessment of cardiac silhouette
  • The infant's Clinician has concern regarding clinical stability and tolerability of ultrasound scans
  • The infant's skin integrity will not tolerate ultrasound gel
  • Refusal of informed consent by their parent/guardian/legally acceptable representative
  • The infant does not have a parent/guardian who can provide informed consent.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Arun Sett, PhD contact

+61405491595

Arun.Sett@wh.org.au

Australia1 site, 1 recruiting
  • Joan Kirner Women's and Children's, Sunshine Hospital, Western Health

    Melbourne, Victoria, 3021

    Aun Sett, MBBS CCPU FRACP PhD, +6190552463, Arun.Sett@wh.org.au

    Recruiting

Other trials in Australia

About this study

Official title: Lung Ultrasound to Reduce the Number of Chest X-rays in Very Preterm Infants in the First 2 Weeks After Birth: A Randomised Controlled Trial

Being born too early (preterm birth) is the leading cause of death in children world-wide. In Australia, 97% of very preterm babies who are admitted to Neonatal Intensive Care Units need breathing support after birth to survive. Despite this significant global impact, neonatal clinicians have few tools available to guide breathing support. Currently, the only lung imaging tool that is routinely used in the Neonatal Intensive Care Unit is a chest X-ray. To reduce radiation exposure, chest X-rays are usually only performed one or two times a day. As chronic lung disease in babies who survive preterm birth is increasing, there is an urgent need to develop new ways to monitor the lungs of these fragile babies.

Lung ultrasound is a form of imaging that is fast, gentle and radiation free. However, it has not been routinely adopted into caring for preterm babies in most countries. This is because there are no randomised controlled trials that have demonstrated the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. The investigators will conduct a randomised controlled trial to demonstrate that lung ultrasound is a quick, safe and accurate alternative to chest x-rays in preterm babies.

Read the detailed description

Preterm babies are born with underdeveloped, fragile lungs and commonly develop respiratory distress syndrome. In Australia, 97% of preterm babies who are admitted to Neonatal Intensive Care Units need breathing support after birth. Respiratory support is vital to keep babies alive but is associated with short- and long-term lung damage. Unfortunately, many babies who survive preterm birth develop bronchopulmonary dysplasia (BPD), leading to poor health outcomes in adulthood.(2) Despite years of research, chronic lung disease is increasing.

Clearly, it is critical that clinicians have effective tools to guide breathing support. Currently, the only lung imaging tool that is routinely used in the Neonatal Intensive Care Unit is chest X-ray (CXR). The fundamental principle of use of ionising radiation in any population is to limit radiation exposure to as low as reasonably achievable (ALARA). To achieve this currently, the use of CXR is usually limited to once or twice a day. In addition CXR are performed by a specialised technician and are not always immediately available, delaying the time to diagnosis. Given the rapid and unpredictable changes in a preterm baby's lung disease, reliance on repeated CXR is fraught with risk. There is an urgent need to develop reliable tools that provides real-time and accurate feedback to guide breathing support in preterm babies.

New monitoring tools should be safe and improve outcomes. Lung ultrasound is a gentle form of lung imaging that is ideally suited for preterm babies. It is radiation free, readily available and does not require excessive handling of the baby. Ultrasound is already routinely used to image the brain and hearts of preterm babies and systems are available in all Neonatal Intensive Care Units in Australia. Several observational studies have demonstrated that lung ultrasound is accurate in diagnosing common neonatal respiratory disorders including pneumothorax, respiratory distress syndrome, transient tachypnoea of the newborn and the need for mechanical ventilation. Not all features of lung ultrasound are interchangeable with CXR measures of lung aeration in preterm infants. Lung ultrasound has a stronger relationship with an infant's respiratory support requirements than CXR. Only one study to date has assessed the ability of lung ultrasound to guide surfactant replacement in a randomized setting. Despite the growing body of evidence that lung ultrasound may be a suitable alternative to CXR, it has not been routinely adopted into clinical practice. This is because no randomized controlled trial has assessed the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. Furthermore, despite no evidence of benefit, some centres have already implemented lung ultrasound into routine practice. Before lung ultrasound can be widely implemented in preterm babies, it must be demonstrated to be beneficial and safe.

The investigators hypothesise that in preterm babies born <32 weeks' gestation, lung ultrasound will significantly reduce radiation exposure and be a safe alternative to CXR. This will be addressed by conducting an open label, randomised controlled trial at Joan Kirner Women's and Children's, Sunshine Hospital, Victoria.

The primary aim of this study is to evaluate whether the use of lung ultrasound as the primary lung imaging modality in preterm babies born <32 weeks' gestation reduces radiation burden.

Secondary aims include assessment of the safety and acceptability of lung ultrasound as the first line imaging tool, and additional signals of benefit including time to receive lung imaging and initiation of treatment, and duration of breathing support. To assess safety, the investigators will report the rate of key protocol defined adverse and serious adverse events in the intervention and control groups. Feasibility will be determined by protocol defined criteria for operational and clinical feasibility. Cost effectiveness will be determined by reporting the microcosts of each imaging tool and comparing the differential costs between the lung ultrasound and chest X-ray. Finally, the investigators will assess the acceptability to neonatal healthcare workers of lung ultrasound as the first-line imaging tool.

Being tested
Lung ultrasound group, Standard Care
Keywords
Lung ultrasound, Respiratory Distress Syndrome, Prematurity
Medical subject headings
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome, Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lung ultrasound groupDevice

    Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.

  • Standard CareDiagnostic test

    Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.

Study groups in NCT06975189
Study groupRoleWhat they receive
Lung ultrasound groupExperimentalInfants randomised to this group will have lung ultrasound as their first
Receives: Device: Lung ultrasound group
Standard careActive comparatorInfants in the standard arm will receive chest X-ray as their first form of lung imaging. Lung ultrasound will not be permitted in this group.
Receives: Diagnostic Test: Standard Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The mean difference in number of x-rays and radiation exposure in the intervention group

    The total number of chest X-rays performed in the study period

    Measured: Until day 14 of life

Secondary outcomes (5)
  1. The mean difference of X-rays for entire admission (until discharge or death)

    Total number of x-rays performed from enrolment in study until death or discharge from hospital

    Measured: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 12 months

  2. The mean difference of X-rays and radiation exposure by gestational age at birth

    The total number of CXR performed in the study period stratified by gestational groups (< 28 weeks' gestation and >/= to 28 weeks' gestation)

    Measured: Until day 14 of life

  3. Time to administering surfactant if clinically indicated

    The mean difference in minutes to administer surfactant if clinically indicted between the lung ultrasound and chest x-ray groups

    Measured: Until day 14 of life

  4. Proportion of infants in the intervention arm who require CXR as first-line imaging due to lung ultrasound not being available

    The number of CXRs performed after a lung ultrasound is performed in the intervention group due to the ultrasound clinicians or system not being available.

    Measured: Until day 14 of life

  5. Cost-effectiveness

    The differential costs between the intervention and control groups determine from a time-in-motion analysis of a pre-determined sub sample of the study population (n=10 patients per group)

    Measured: Until day 14 of life

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2025
  2. Study start13 Apr 2026
  3. Primary completion1 Aug 2029 (estimated)
  4. Study completion1 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
180 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06975189
Sponsor's protocol ID
115953
Acronym
MINI T-Rex
Status last verified
Apr 2026
First submitted
9 Apr 2025
Last updated
16 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual patient data will be shared to research parties who have a sound research proposal and prior institutional review board approval.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Lung ultrasound group in people with Neonatal Respiratory Distress Syndrome and PreTerm Neonate, run by Western Health, Australia at 1 site in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Arun Sett, PhD (+61405491595, Arun.Sett@wh.org.au), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The mean difference in number of x-rays and radiation exposure in the intervention group (time frame: Until day 14 of life). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in